Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1

Controllable drug uptake and nongenomic response through estrogen-anchored cyclodextrin drug complex

Authors Yin JJ, Shumyak SP, Burgess C, Zhou ZW, He ZX, Zhang XJ, Pan ST, Yang T, Duan W, Qiu JX, Zhou SF

Received 5 February 2015

Accepted for publication 18 March 2015

Published 27 July 2015 Volume 2015:10(1) Pages 4717—4730

DOI https://doi.org/10.2147/IJN.S82255

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Thomas J Webster

Juan-Juan Yin,1,2 Stepan P Shumyak,2 Christopher Burgess,2 Zhi-Wei Zhou,2 Zhi-Xu He,3 Xue-Ji Zhang,4 Shu-Ting Pan,2,5 Tian-Xin Yang,6 Wei Duan,7 Jia-Xuan Qiu,5 Shu-Feng Zhou2

1
Xiaolan People’s Hospital, Southern Medical University, Zhongshan, Guangdong, People’s Republic of China; 2Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA; 3Guizhou Provincial Key Laboratory for Regenerative Medicine, Stem Cell and Tissue Engineering Research Center and Sino-US Joint Laboratory for Medical Sciences, Guizhou Medical University, Guiyang, Guizhou, 4Research Center for Bioengineering and Sensing Technology, University of Science and Technology Beijing, Beijing, 5Department of Oral and Maxillofacial Surgery, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People’s Republic of China; 6Department of Internal Medicine, University of Utah and Salt Lake Veterans Affairs Medical Center, Salt Lake City, UT, USA; 7School of Medicine, Deakin University, Waurn Ponds, VIC, Australia

Abstract: Breast cancer is a leading killer of women worldwide. Cyclodextrin-based estrogen receptor-targeting drug-delivery systems represent a promising direction in cancer therapy but have rarely been investigated. To seek new targeting therapies for membrane estrogen receptor-positive breast cancer, an estrogen-anchored cyclodextrin encapsulating a doxorubicin derivative Ada-DOX (CDE1-Ada-DOX) has been synthesized and evaluated in human breast cancer MCF-7 cells. First, we synthesized estrone-conjugated cyclodextrin (CDE1), which formed the complex CDE1-Ada-DOX via molecular recognition with the derivative adamantane-doxorubicin (Ada-DOX) (Kd=1,617 M-1). The structure of the targeting vector CDE1 was fully characterized using 1H- and 13C-nuclear magnetic resonance, mass spectrometry, and electron microscopy. CDE1-Ada-DOX showed two-phase drug-release kinetics with much slower release than Ada-DOX. The fluorescence polarization analysis reveals that CDE1-Ada-DOX binds to recombinant human estrogen receptor α fragments with a Kd of 0.027 µM. Competition assay of the drug complex with estrogen ligands demonstrated that estrone and tamoxifen competed with CDE1-Ada-DOX for membrane estrogen receptor binding in MCF-7 cells. Intermolecular self-assembly of CDE1 molecules were observed, showing tail-in-bucket and wire-like structures confirmed by transmission electronic microscopy. CDE1-Ada-DOX had an unexpected lower drug uptake (when the host–guest ratio was >1) than non-targeting drugs in MCF-7 cells due to ensconced ligands in cyclodextrins cavities resulting from the intermolecular self-assembly. The uptake of CDE1-Ada-DOX was significantly increased when the host–guest ratio was adjusted to be less than half at the concentration of CDE1 over 5 µM due to the release of the estrone residues. CDE1 elicited rapid activation of mitogen-activated protein kinases (p44/42 MAPK, Erk1/2) in minutes through phosphorylation of Thr202/Tyr204 in MCF-7 cells. These results demonstrate a targeted therapeutics delivery of CDE1-Ada-DOX to breast cancer cells in a controlled manner and that the drug vector CDE1 can potentially be employed as a molecular tool to differentiate nongenomic from genomic mechanism.

Keywords: breast cancer, drug vector, functionalized, membrane estrogen receptor, polysaccharide, targeted drug delivery

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells

Pan ST, Qin Y, Zhou ZW, He ZX, Zhang X, Yang T, Yang YX, Wang D, Zhou SF, Qiu JX

Drug Design, Development and Therapy 2015, 9:5511-5551

Published Date: 5 October 2015

High-throughput sequencing of 16S rDNA amplicons characterizes bacterial composition in cerebrospinal fluid samples from patients with purulent meningitis

Liu A, Wang C, Liang Z, Zhou ZW, Wang L, Ma Q, Wang G, Zhou SF, Wang Z

Drug Design, Development and Therapy 2015, 9:4417-4429

Published Date: 7 August 2015

Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study

Niu NK, Yin JJ, Yang YX, Wang ZL, Zhou ZW, He ZX, Chen XW, Zhang XJ, Duan W, Yang TX, Zhou SF

Drug Design, Development and Therapy 2015, 9:4441-4470

Published Date: 7 August 2015

Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer

Ren T, Shan J, Li M, Qing Y, Qian C, Wang G, Li Q, Lu G, Li C, Peng Y, Luo H, Zhang S, Yang Y, Cheng Y, Wang D, Zhou SF

Drug Design, Development and Therapy 2015, 9:2887-2910

Published Date: 8 June 2015

Schisandrin B inhibits cell growth and induces cellular apoptosis and autophagy in mouse hepatocytes and macrophages: implications for its hepatotoxicity

Zhang Y, Zhou ZW, Jin H, Hu C, He ZX, Yu ZL, Ko KM, Yang T, Zhang X, Pan SY, Zhou SF

Drug Design, Development and Therapy 2015, 9:2001-2027

Published Date: 9 April 2015

Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells

Pan ST, Qin Y, Zhou ZW, He ZX, Zhang X, Yang T, Yang YX, Wang D, Qiu JX, Zhou SF

Drug Design, Development and Therapy 2015, 9:1601-1626

Published Date: 16 March 2015

Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells

Zhou ZW, Li XX, He ZX, Pan ST, Yang Y, Zhang X, Chow K, Yang T, Qiu JX, Zhou Q, Tan J, Wang D, Zhou SF

Drug Design, Development and Therapy 2015, 9:1511-1554

Published Date: 12 March 2015

Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells

Wang YY, Yang YX, Zhao R, Pan ST, Zhe H, He ZX, Duan W, Zhang X, Yang TX, Qiu JX, Zhou SF

Drug Design, Development and Therapy 2015, 9:993-1026

Published Date: 17 February 2015

The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells

Li JP, Yang YX, Liu QL, Zhou ZW, Pan ST, He ZX, Zhang X, Yang T, Pan SY, Duan W, He SM, Chen XW, Qiu JX, Zhou SF

Drug Design, Development and Therapy 2015, 9:1027-1062

Published Date: 17 February 2015

Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells

Wang F, Wang Q, Zhou ZW, Yu SN, Pan ST, He ZX, Zhang X, Wang D, Yang YX, Yang T, Sun T, Li M, Qiu JX, Zhou SF

Drug Design, Development and Therapy 2015, 9:537-560

Published Date: 17 January 2015

Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells

Wang F, Li H, Yan XG, Zhou ZW, Yi ZG, He ZX, Pan ST, Yang YX, Wang ZZ, Zhang X, Yang T, Qiu JX, Zhou SF

Drug Design, Development and Therapy 2015, 9:575-601

Published Date: 17 January 2015

Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells

Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, Yang T, Wang NJ, Zhao RJ, Zhou SF

Drug Design, Development and Therapy 2015, 9:487-508

Published Date: 14 January 2015

Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells

Ding YH, Zhou ZW, Ha CF, Zhang XY, Pan ST, He ZX, Edelman JL, Wang D, Yang ZX, Zhang XJ, Duan W, Yang TX, Qiu JX, Zhou SF

Drug Design, Development and Therapy 2015, 9:425-464

Published Date: 9 January 2015

An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides

Cheng J, Zhou ZW, Sheng HP, He LJ, Fan XW, He ZX, Sun T, Zhang X, Zhao RJ, Gu L, Cao CH, Zhou SF

Drug Design, Development and Therapy 2015, 9:33-78

Published Date: 17 December 2014

Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: a bioinformatic and animal study

Su JH, Chang C, Xiang Q, Zhou ZW, Luo R, Yang L, He ZX, Yang HT, Li J, Bei Y, Xu JM, Zhang MJ, Zhang QH, Su ZJ, Huang YD, Pang JY, Zhou SF

Drug Design, Development and Therapy 2014, 8:2555-2602

Published Date: 12 December 2014

Matrix-induced autologous chondrocyte implantation for the treatment of chondral defects of the knees in Chinese patients

Zhang ZW, Zhong X, Ji HR, Tang ZB, Bai JP, Yao MM, Hou JL, Zheng MH, Wood D, Sun JZ, Zhou SF, Liu AB

Drug Design, Development and Therapy 2014, 8:2439-2448

Published Date: 5 December 2014

Readers of this article also read:

Cytotoxicity and physicochemical characterization of iron–manganese-doped sulfated zirconia nanoparticles [Corrigendum]

Al-Fahdawi MQ, Rasedee A, Al-Qubaisi MS, Alhassan FH, Rosli R, El Zowalaty ME, Naadja SE, Webster TJ, Taufiq-Yap YH

International Journal of Nanomedicine 2015, 10:6657-6658

Published Date: 28 October 2015

pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery

Yao Y, Su ZH, Liang YC, Zhang N

International Journal of Nanomedicine 2015, 10:6185-6198

Published Date: 1 October 2015

Codelivery of SH-aspirin and curcumin by mPEG-PLGA nanoparticles enhanced antitumor activity by inducing mitochondrial apoptosis

Zhou L, Duan X, Zeng S, Men K, Zhang X, Yang L, Li X

International Journal of Nanomedicine 2015, 10:5205-5218

Published Date: 18 August 2015

Fiber-optic triggered release of liposome in vivo: implication of personalized chemotherapy

Huang HL, Lu PH, Yang HC, Lee GD, Li HR, Liao KC

International Journal of Nanomedicine 2015, 10:5171-5185

Published Date: 14 August 2015

Blood group antigen studies using CdTe quantum dots and flow cytometry

Cabral Filho PE, Pereira MIA, Fernandes HP, de Thomaz AA, Cesar CL, Santos BS, Barjas-Castro ML, Fontes A

International Journal of Nanomedicine 2015, 10:4393-4404

Published Date: 8 July 2015

Chitosan–tripolyphosphate nanoparticles as Arrabidaea chica standardized extract carrier: synthesis, characterization, biocompatibility, and antiulcerogenic activity

Servat-Medina L, González-Gómez A, Reyes-Ortega F, Sousa IMO, Queiroz NCA, Zago PMW, Jorge MP, Monteiro KM, de Carvalho JE, San Román J, Foglio MA

International Journal of Nanomedicine 2015, 10:3897-3909

Published Date: 9 June 2015

Nanofabrication of methylglyoxal with chitosan biopolymer: a potential tool for enhancement of its anticancer effect

Pal A, Talukdar D, Roy A, Ray S, Mallick A, Mandal C, Ray M

International Journal of Nanomedicine 2015, 10:3499-3518

Published Date: 12 May 2015

Reduction-responsive cross-linked stearyl peptide for effective delivery of plasmid DNA

Yao C, Tai Z, Wang X, Liu J, Zhu Q, Wu X, Zhang L, Zhang W, Tian J, Gao Y, Gao S

International Journal of Nanomedicine 2015, 10:3403-3416

Published Date: 8 May 2015